Clinical Trials Logo
  1. Home
  2. Lymphoma, Non-Hodgkin's
  3. NCT02750670

Obinutuzumab in Combination With GDP Chemotherapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Lymphoma, Non-Hodgkin's Clinical Trial

Official title:
Pilot Study of Obinutuzumab in Combination With GDP Chemotherapy for the Treatment of Relapsed or Refractory CD20+ Aggressive Non-Hodgkin Lymphoma

Clinical Trial Summary

This is a pilot study to determine the overall survival rate and toxicities of obinutuzumab given with GDP chemotherapy for relapsed or refractory CD20+ aggressive non-Hodgkin lymphoma. Patients who have CD20+ and progressed R-CHOP therapy will be enrolled into the study. About 30 patients are planned to be enrolled from Princess Margaret Cancer Centre. If the enrollment is very slow then additional site may be included. Patients will receive Obinutuzumab +GDP for 3 cycles intravenously. CT scan will be used to evaluate the response rate after cycle 2 and PET-CT will be used after cycle 3. Responders (complete metabolic response, partial metabolic response) should proceed to autologous stem cell transplant (ASCT). Patients who have progressed after three cycles or less are to have their protocol treatment discontinued, with subsequent treatment at investigator discretion. Patients will be followed up to 24 months from transplant done or last chemo. Mandatory tissue submission and optional tissue and blood submission are required for the correlative component of this study.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02750670
Study type Interventional
Source University Health Network, Toronto
Contact
Status Completed
Phase Phase 2
Start date March 15, 2017
Completion date February 9, 2021
View Details
See also
  Status Clinical Trial Phase
Terminated NCT00363636 - A Study of Galiximab + Rituximab Versus Rituximab + Placebo in Follicular Non-Hodgkin's Lymphoma (NHL) Phase 3
Terminated NCT00594308 - In-Vivo Activated T-Cell Depletion to Prevent GVHD N/A
Terminated NCT02518750 - Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma Phase 2
Completed NCT01733238 - Study of PNT2258 for Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma Phase 2
Terminated NCT00384150 - Retreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma (NHL) Phase 3
Terminated NCT00141700 - Study of Rituximab Plus High-Dose Chemotherapy Poor Prognosis Non-Hodgkin's Lymphoma Phase 2
Terminated NCT00143884 - Study of Low Intensity Conditioning and Immunotherapy for High-Risk Cancers of the Blood Phase 2
Terminated NCT02473523 - Yoga to Alleviate Fatigue, Anxiety and Pain in Adolescents During Treatment for Lymphoma or Leukemia N/A
Completed NCT00413036 - A Study of Revlimid in the Treatment of Non-Hodgkin's Lymphoma Phase 2
Completed NCT00161590 - Study of CHOP + Campath for T-Cell, Null Cell, or Natural Killer (NK)-Cell Lymphoma Phase 1
Terminated NCT00651443 - Mechanism of Action of Galiximab in Subjects With Previously Untreated Follicular Non-Hodgkin's Lymphoma Phase 1
Recruiting NCT04756726 - Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma Phase 1/Phase 2
Terminated NCT00395967 - AMD3100 (Plerixafor) in Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL) Patients Predicted to be Unable to Mobilize With G-CSF Alone Phase 2
Completed NCT00143871 - Study of Rituximab Plus High-Dose Chemotherapy Non-Hodgkin's Lymphoma Phase 2